Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease

Laura Barisoni-Thomas, J. Charles Jennette, Robert Colvin, Sheela Sitaraman, Alexander Bragat, Jeff Castelli, Dan Walker, Pol Boudes

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Context. - Assessing the amount of globotriaosylceramide inclusions in renal peritubular capillaries by a semiquantitative approach is a standard and useful measure of therapeutic efficacy in Fabry disease, achievable by light microscopy analysis. Objective. - To describe a novel virtual microscopy quantitative method to measure globotriaosylceramide inclusions (Barisoni Lipid Inclusion Scoring System [BLISS]) in renal biopsies from patients with Fabry disease. Design. - Plastic embedded 1-mm-thick sections from kidney biopsies from 17 patients enrolled in a Fabry disease clinical trial were evaluated using a standard semiquantitative methodology and BLISS to compare sensitivity. We also tested intrareader and interreader variability of BLISS and compared results from conventional light microscopy analysis with a virtual microscopy-based methodology. Peritubular capillaries were first annotated on digital images of whole slides by 1 pathologist and then scored for globotriaosylceramide inclusions by 2 additional pathologists. Results. - We demonstrated that (1) quantitative analysis by BLISS results in detection of small amount of globotriaosylceramide inclusions even when by semiquantitative analysis the score is 0, (2) application of BLISS combined with conventional light microscopy results in low intrareader and interreader variability, and (3) BLISS combined with virtual microscopy results in significant reduction of intrareader and interreader variability compared with BLISS-light microscopy. Conclusions. - BLISS is a simpler and more sensitive scoring system compared to the semiquantitative approach. The virtual microscopy-based methodology increases accuracy and reproducibility; moreover, it provides a permanent record of retrievable data with full transparency in clinical trials.

Original languageEnglish
Pages (from-to)816-824
Number of pages9
JournalArchives of Pathology and Laboratory Medicine
Volume136
Issue number7
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Fabry Disease
Microscopy
Kidney
Lipids
Light
Clinical Trials
Biopsy
globotriaosylceramide
Plastics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease. / Barisoni-Thomas, Laura; Jennette, J. Charles; Colvin, Robert; Sitaraman, Sheela; Bragat, Alexander; Castelli, Jeff; Walker, Dan; Boudes, Pol.

In: Archives of Pathology and Laboratory Medicine, Vol. 136, No. 7, 01.07.2012, p. 816-824.

Research output: Contribution to journalArticle

Barisoni-Thomas, Laura ; Jennette, J. Charles ; Colvin, Robert ; Sitaraman, Sheela ; Bragat, Alexander ; Castelli, Jeff ; Walker, Dan ; Boudes, Pol. / Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease. In: Archives of Pathology and Laboratory Medicine. 2012 ; Vol. 136, No. 7. pp. 816-824.
@article{ec1b68d66496498889db20cba01db029,
title = "Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease",
abstract = "Context. - Assessing the amount of globotriaosylceramide inclusions in renal peritubular capillaries by a semiquantitative approach is a standard and useful measure of therapeutic efficacy in Fabry disease, achievable by light microscopy analysis. Objective. - To describe a novel virtual microscopy quantitative method to measure globotriaosylceramide inclusions (Barisoni Lipid Inclusion Scoring System [BLISS]) in renal biopsies from patients with Fabry disease. Design. - Plastic embedded 1-mm-thick sections from kidney biopsies from 17 patients enrolled in a Fabry disease clinical trial were evaluated using a standard semiquantitative methodology and BLISS to compare sensitivity. We also tested intrareader and interreader variability of BLISS and compared results from conventional light microscopy analysis with a virtual microscopy-based methodology. Peritubular capillaries were first annotated on digital images of whole slides by 1 pathologist and then scored for globotriaosylceramide inclusions by 2 additional pathologists. Results. - We demonstrated that (1) quantitative analysis by BLISS results in detection of small amount of globotriaosylceramide inclusions even when by semiquantitative analysis the score is 0, (2) application of BLISS combined with conventional light microscopy results in low intrareader and interreader variability, and (3) BLISS combined with virtual microscopy results in significant reduction of intrareader and interreader variability compared with BLISS-light microscopy. Conclusions. - BLISS is a simpler and more sensitive scoring system compared to the semiquantitative approach. The virtual microscopy-based methodology increases accuracy and reproducibility; moreover, it provides a permanent record of retrievable data with full transparency in clinical trials.",
author = "Laura Barisoni-Thomas and Jennette, {J. Charles} and Robert Colvin and Sheela Sitaraman and Alexander Bragat and Jeff Castelli and Dan Walker and Pol Boudes",
year = "2012",
month = "7",
day = "1",
doi = "10.5858/arpa.2011-0350-OA",
language = "English",
volume = "136",
pages = "816--824",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "7",

}

TY - JOUR

T1 - Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease

AU - Barisoni-Thomas, Laura

AU - Jennette, J. Charles

AU - Colvin, Robert

AU - Sitaraman, Sheela

AU - Bragat, Alexander

AU - Castelli, Jeff

AU - Walker, Dan

AU - Boudes, Pol

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Context. - Assessing the amount of globotriaosylceramide inclusions in renal peritubular capillaries by a semiquantitative approach is a standard and useful measure of therapeutic efficacy in Fabry disease, achievable by light microscopy analysis. Objective. - To describe a novel virtual microscopy quantitative method to measure globotriaosylceramide inclusions (Barisoni Lipid Inclusion Scoring System [BLISS]) in renal biopsies from patients with Fabry disease. Design. - Plastic embedded 1-mm-thick sections from kidney biopsies from 17 patients enrolled in a Fabry disease clinical trial were evaluated using a standard semiquantitative methodology and BLISS to compare sensitivity. We also tested intrareader and interreader variability of BLISS and compared results from conventional light microscopy analysis with a virtual microscopy-based methodology. Peritubular capillaries were first annotated on digital images of whole slides by 1 pathologist and then scored for globotriaosylceramide inclusions by 2 additional pathologists. Results. - We demonstrated that (1) quantitative analysis by BLISS results in detection of small amount of globotriaosylceramide inclusions even when by semiquantitative analysis the score is 0, (2) application of BLISS combined with conventional light microscopy results in low intrareader and interreader variability, and (3) BLISS combined with virtual microscopy results in significant reduction of intrareader and interreader variability compared with BLISS-light microscopy. Conclusions. - BLISS is a simpler and more sensitive scoring system compared to the semiquantitative approach. The virtual microscopy-based methodology increases accuracy and reproducibility; moreover, it provides a permanent record of retrievable data with full transparency in clinical trials.

AB - Context. - Assessing the amount of globotriaosylceramide inclusions in renal peritubular capillaries by a semiquantitative approach is a standard and useful measure of therapeutic efficacy in Fabry disease, achievable by light microscopy analysis. Objective. - To describe a novel virtual microscopy quantitative method to measure globotriaosylceramide inclusions (Barisoni Lipid Inclusion Scoring System [BLISS]) in renal biopsies from patients with Fabry disease. Design. - Plastic embedded 1-mm-thick sections from kidney biopsies from 17 patients enrolled in a Fabry disease clinical trial were evaluated using a standard semiquantitative methodology and BLISS to compare sensitivity. We also tested intrareader and interreader variability of BLISS and compared results from conventional light microscopy analysis with a virtual microscopy-based methodology. Peritubular capillaries were first annotated on digital images of whole slides by 1 pathologist and then scored for globotriaosylceramide inclusions by 2 additional pathologists. Results. - We demonstrated that (1) quantitative analysis by BLISS results in detection of small amount of globotriaosylceramide inclusions even when by semiquantitative analysis the score is 0, (2) application of BLISS combined with conventional light microscopy results in low intrareader and interreader variability, and (3) BLISS combined with virtual microscopy results in significant reduction of intrareader and interreader variability compared with BLISS-light microscopy. Conclusions. - BLISS is a simpler and more sensitive scoring system compared to the semiquantitative approach. The virtual microscopy-based methodology increases accuracy and reproducibility; moreover, it provides a permanent record of retrievable data with full transparency in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84864261116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864261116&partnerID=8YFLogxK

U2 - 10.5858/arpa.2011-0350-OA

DO - 10.5858/arpa.2011-0350-OA

M3 - Article

C2 - 22742555

AN - SCOPUS:84864261116

VL - 136

SP - 816

EP - 824

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 7

ER -